The DOI matches its Crossref record; 97 of the 98 references it cites were found in a registry or an index.
Does cellular iron dysregulation play a causative role in Parkinson’s disease?
Abstract
Selective dopaminergic cell loss in Parkinson's disease is correlated with increased levels of cellular iron. It is still hotly debated as to whether the increase in iron is an upstream event which acts to promote neurodegeneration via formation of oxidative stress or whether iron accumulates as a by-product of the neuronal cell loss. Here we review evidence for loss of iron homeostasis as a causative factor in disease-associated neurodegeneration and the primary players which may be involved. A series of recent studies suggest that iron regulatory proteins (IRPs) coordinate both cellular iron levels and energy metabolism, both of which are disrupted in Parkinson's disease (PD) and may in turn contribute to increased levels of oxidative stress associated with the disease. Iron has also been recently been implicated in promotion of alpha-synuclein aggregation either directly or via increasing levels of oxidative stress suggesting an important role for it in Lewy body formation, another important hallmark of the disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“When ferritin H was transgenically overexpressed into Parkinson disease (PD) model mice, reduced oxidative stress was found (159).”
From Intracellular iron transport and storage: from molecular mechanisms to health implications (2008) · cites this paper as [159]
In the citing paper
“In addition, overexpression of ferritin H protected cells from the toxicity of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a drug used to create experimental models of PD) (159).”
From Intracellular iron transport and storage: from molecular mechanisms to health implications (2008) · cites this paper as [159]
In the citing paper
“Chelation of “labile iron” also protected cells from this toxicity, suggesting that iron may play a role in the pathogenesis of PD, at least in the MPTP model (159).”
From Intracellular iron transport and storage: from molecular mechanisms to health implications (2008) · cites this paper as [159]
In the citing paper
“Chelation of “labile iron” also protected cells from this toxicity, suggesting that iron may play a role in the pathogenesis of PD, at least in the MPTP model (159).”
From Intracellular iron transport and storage: from molecular mechanisms to health implications (2008) · cites this paper as [159]
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. A., & SEITELBERGER, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,650
Wiklund, R. A., & Rosenbaum, S. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371606 · Cited by 2,153
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,072
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Giasson, B. I., Duda, J. E., Murray, I. V. J., Chen, Q., Souza, J. M., Hurtig, H. I., Ischiropoulos, H., Trojanowski, J. Q., & Lee, V. M. ‐. (2000) · Science · doi:10.1126/science.290.5493.985 · Cited by 1,567
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383
Hentze, M. W., & Kühn, L. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8175 · Cited by 1,292
Parkinson's disease. Second of two parts.
Lang, A., & Lozano, A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391607 · Cited by 1,193
Flagged first, then by citations
1 of the 98 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Oxidative Stress and Neurotoxicity
Sayre, L. M., Perry, G. L., & Smith, M. A. (2007) · Chemical Research in Toxicology · doi:10.1021/tx700210j · Cited by 884
Green tea and its polyphenolic catechins: Medicinal uses in cancer and noncancer applications
Zaveri, N. T. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.006 · Cited by 811
Oxidative Stress and Antioxidants in Neurodegenerative Disorders
Olufunmilayo, E. O., Gerke-Duncan, M. B., & Holsinger, R. M. D. (2023) · Antioxidants · doi:10.3390/antiox12020517 · Cited by 752
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Metadata
- Authors
- Kaur, D., & Andersen, J.
- Affiliations
- Buck Institute for Research on Aging (US)
- Corresponding author
- Andersen, Julie
- ORCID
- Andersen, Julie
- Venue
- Ageing Research Reviews
- Publisher
- Elsevier BV
- Published
- 2004-07
- Volume
- 3
- Issue
- 3
- Pages
- 327-343
- ISSN
- 1568-1637 (ISSN-L)
- OpenAlex
- W1998032181
- Cited by
- 123
- References
- 98
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 6 · 2020: 4 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 7 · 2015: 1 · 2014: 2 · 2013: 8 · 2012: 7
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Ageing Research Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (AG-12141)
- National Institute of Neurological Disorders and Stroke (R01NS041264, NS41264)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Keywords
- Parkinson's disease, iron homeostasis, iron regulatory proteins, oxidative stress, dopaminergic neuron loss, neurodegeneration, alpha-synuclein aggregation, Lewy bodies, energy metabolism
- MeSH terms
- Animals, Homeostasis, Humans, Iron, Mesencephalon, Mitochondria, Models, Biological, Nerve Tissue Proteins, Parkinson Disease, Protein Binding, Oxidative Stress, Neurodegenerative Diseases, Iron-Regulatory Proteins, Iron Regulatory Protein 1, Iron Regulatory Protein 2, Synucleins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
